LTS and Nualtis Forge Strategic Alliance to Elevate Global Manufacturing and Market Reach

LTS and Nualtis Join Forces for Advanced Drug Manufacturing

In an exciting development for the pharmaceutical industry, LTS LOHMANN Therapie-Systeme AG (LTS) and Nualtis, an innovator in oral thin film drug delivery systems, have announced their strategic alliance aimed at enhancing manufacturing capabilities and expanding market outreach. This collaboration, revealed on June 25, 2025, presents a comprehensive approach to improving patient outcomes through cutting-edge drug delivery technologies.

Accelerating Growth and Innovation

Under this strategic partnership, LTS will utilize its extensive expertise in technology transfer, scale-up, and manufacturing to support Nualtis's innovative oral thin film (OTF) products. This partnership not only offers Nualtis the necessary resources to scale its operations but also aims to ensure that patients across the globe have access to high-quality, reliable medications.

Nualtis has been a game-changer in the field of OTF technologies, continually pushing the boundaries of innovation. As they expand their pipeline of novel OTF solutions, this partnership will enable greater supply chain flexibility, ensuring that partners are equipped with the necessary support from early development stages to full-scale commercialization.

Dr. Michael Raven, the CEO of Nualtis, emphasized that this collaboration marks a new growth phase for his company, providing additional manufacturing capabilities that enhance the overall confidence of their partners in the supply chain process.

Joint Commitment to Quality and Scalability

With LTS's leading position in the OTF market, the collaboration highlights the company’s commitment to delivering not just products but exceptional outcomes for health professionals and patients alike. LTS has a rich history of advancing drug delivery systems, including developing transdermal patches and wearable devices, and they aim to leverage this expertise further through this collaboration.

Among the core principles guiding LTS's operations—